Evidence map›Paper›PMID 42233169›Full record

ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Heat Shock Protein 90: From Molecular Chaperone Function to Therapeutic Targeting in Malignancies.

Beibei Zhang, Xinxin Zou, Jiansong Zhou, Qinmiao Sun, Dahua Chen

Abstract readReview
In one paragraph

Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Beibei ZhangInstitute of Biomedical Research, Yunnan University, Kunming, Yunnan, China.ORCID https://orcid.org/0000-0002-7231-360X
Xinxin ZouInstitute of Biomedical Research, Yunnan University, Kunming, Yunnan, China.
Jiansong ZhouInstitute of Biomedical Research, Yunnan University, Kunming, Yunnan, China.
Qinmiao SunState Key Laboratory of Organ Regeneration and Reconstruction, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
Dahua ChenInstitute of Biomedical Research, Yunnan University, Kunming, Yunnan, China.ORCID https://orcid.org/0000-0002-2122-9141

Funding

Basic Science Center Program of NSFC 31988101Excellence Research Group Program of NSFC 32588201National Natural Science Foundation of China 82260038Yunnan Province Science and Technology Department 202105AB160002Yunnan Province Science and Technology Department 202305AS350022Yunnan Province Science and Technology Department 202305AT350003Yunnan Province Science and Technology Department 202501AT070207Yunnan Province Science and Technology Department 202601AS070039
6 · The paper itself

Abstract

Heat shock protein 90 (HSP90) is an evolutionarily conserved molecular chaperone that occupies a central position in cellular proteostasis and adaptation to stress. By promoting protein folding and facilitating the functional activation of a broad repertoire of clients, HSP90 underpins essential cellular processes, including development, proliferation, differentiation, and stress responses. In cancer, this extensive network renders tumor cells highly dependent on HSP90 to maintain oncogenic signaling, tolerate proteotoxic stress, and survive therapeutic insults. In this review, we propose an integrated conceptual framework linking HSP90's molecular chaperone functions to its pathological roles in cancer: HSP90 serves as a central node that concurrently supports oncogenic signaling, buffers proteotoxic stress, maintains cancer stem cell plasticity, and shapes tumor-immune interactions-all of which converge to drive therapeutic resistance and tumor recurrence. Within this framework, we summarize the molecular mechanisms governing HSP90 activity and dissect its context-dependent roles in cancer progression, drug resistance, and immune regulation. We further highlight recent advances in HSP90-targeted interventions, including small-molecule inhibitors, monoclonal antibodies, engineered immune cells, and emerging strategies designed to prevent, delay, or overcome drug resistance. Taken together, these developments underscore HSP90 as a versatile therapeutic node and point toward innovative, resistance-aware strategies for clinical translation and future research.

Indexed as

HSP90 Heat-Shock ProteinsMolecular ChaperonesNeoplasmsAnimalsHumansMolecular Targeted TherapySignal TransductionHSP90 Heat-Shock ProteinsMolecular Chaperonescancer recurrencedrug resistanceheat shock proteinimmunotherapymolecular chaperone

Identifiers

PMID42233169
PMCPMC13337037

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.